Midatech Pharma Plc EV / EBITDA
Was ist das EV / EBITDA von Midatech Pharma Plc?
EV / EBITDA von Midatech Pharma Plc ist 0.40
Was ist die Definition von EV / EBITDA?
EV / EBITDA ist der Unternehmenswert geteilt durch das Einkommen vor Zinsen, Steuern, Abschreibungen und Amortisationen. Es ist ein Maß dafür, wie teuer eine Aktie ist und für Vergleiche zwischen Unternehmen häufiger gültig ist als das Preis-Gewinn-Verhältnis. Er misst den Preis (in Form des Unternehmenswerts), den ein Investor zu Gunsten des Cashflows des Unternehmens (in Form des EBITDA) bezahlt.
Price to earnings ratios are impacted by a company's choice of capital structure - companies which raise money via debt will have lower P/Es (and therefore look cheaper) than companies that raise an equivalent amount of money by issuing shares, even though the two companies might have equivalent enterprise values. A sample case is when a company with debt were to raise money by issuing shares of stock, and then used the money to pay off the debt, this company's P/E ratio would shoot up because of the increased number of shares - although nothing about the fundamental value of the business has changed. EV / EBITDA is unaffected by capital structure as enterprise value includes the value of debt, and EBITDA is available to all investors (debt and equity) as it excludes interest payments on that debt. It is ideal for analysts and potential investors looking to compare companies within the same industry.
EV / EBITDA von Unternehmen in Health Care Sektor auf LSE im Vergleich zu Midatech Pharma Plc
Was macht Midatech Pharma Plc?
Midatech Pharma plc focuses on the research and development of oncology and rare disease products in the United Kingdom, rest of Europe, and internationally. The company is developing MTX110, a direct delivery treatment for diffuse intrinsic pontine glioma, medulloblastomas, and glioblastoma multiforme; MTX114, an immuno-suppressant for topical application in psoriasis; and MTD211 and MTD219 for central nervous system and transplant anti-rejection indications. It also offers drug delivery platforms, such as Q-Sphera, a polymer microsphere microtechnology used for sustained release drug delivery; MidaSolve, an oligosaccharide nanotechnology used to solubilize drugs so that they can be administered in liquid form directly and locally into tumors; and MidaCore, a gold nanoparticle used for targeting sites of disease by using chemotherapeutic agents or immunotherapeutic agents. The company was founded in 2000 and is headquartered in Cardiff, the United Kingdom.
Unternehmen mit ev / ebitda ähnlich Midatech Pharma Plc
- Northern Bitcoin AG hat EV / EBITDA von 0.39
- Jilin Province Huinan Changlong Bio-pharmacy hat EV / EBITDA von 0.39
- Cassowary Capital hat EV / EBITDA von 0.39
- SciPlay hat EV / EBITDA von 0.40
- Mmtec hat EV / EBITDA von 0.40
- Meat-Tech 3D Ltd hat EV / EBITDA von 0.40
- Midatech Pharma Plc hat EV / EBITDA von 0.40
- Teras Resources hat EV / EBITDA von 0.40
- WestStar Industrial hat EV / EBITDA von 0.40
- Gulfport hat EV / EBITDA von 0.40
- SDX Plc hat EV / EBITDA von 0.40
- Harpoon Therapeutics hat EV / EBITDA von 0.41
- Litho Formas, S.A hat EV / EBITDA von 0.41